晚期非小细胞肺癌HIF-1α、ERCC1基因多态性与铂类药物疗效的关系

Correlation among HIF-1α,ERCC1 genetic polymorphisms and outcome of NSCLC patients receiving platinum-based chemotherapy

目的:探讨HIF-1α和ERCC1基因多态性与铂类药物对NSCLC疗效的相关性。方法:选取我院采用铂类药物治疗的晚期NSCLC患者,经PCR-RFLP方法检查患者HIF-1α基因C1772T和ERCC1基因C118T基因型,分析不同基因型之间化疗疗效的差异。结果:患者HIF-1α基因C1772T和ERCC1基因C118T两个多态位点均符合Hardy-Weinberg遗传平衡规律;携带HIF-1αCT+TT基因型患者的铂类药物治疗有效率显著高于CC型;携带ERCC1 CC基因型患者的铂类药物治疗有效率显著高于CT+TT型。102例患者中有4例失访,98例患者中位TTP为7.0个月,携带HIF-1αCT+TT基因型患者中位TTP为7.0个月,而CC基因型为6.0个月,差异无统计学意义;携带ERCC1 CC基因型患者的中位TTP为7.0个月,而CT+TT基因型为6.0个月,差异无统计学意义。结论 :HIF-1α基因的CT+TT基因型和ERCC1的CC基因型患者的铂类药物化疗有效率高,并且ERCC1的CC基因型患者的预后更好。

Objective To analyze the relationship among HIF-1α, ERCC1 gene polymorphisms and the effects of platinum-based chemotherapy for the treatment of advanced non-small cell lung cancer （NSCLC） Methods HIF-1α C1772T and ERCC1 CIlST loci were genotyped with PCR-RFLP method. The relationship between genotypes and the outcome of treatment as well as TIP was investigated. Results HIF-1α and ERCC1 of 102 patients were under the Hardy-Weinberg equilibrium. Patients with HIF-1α CT＋TT genotype showed a significantly higher chemotherapeutic efficiency compared with patients with CC genotype; Patients with ERCC1 CC genotype showed a significantly higher chemotherapeutic efficiency compared with patients with CT ＋TT genotype. The median TIP was 7.0 months for the 98 patients followed-up; 7.0 months for HIF-1α CT＋TT genotype, and 6.0 months for CC genotype, and the difference showed no significance; The median TIP was 7.0 months for ERCC1 CC genotype, and 6.0 months for CT＋TT genotype, and the difference was statistically significant. Conclusions Patients with HIF-1α CT＋TT genotype or ERCC1 CC genotype have showed higher chemotherapeutic efficiency, and patients with ERCC1 CC genotype show longer median TIP.